Table 5 Factors affecting outcome of therapy in children with at least six months of follow-up on ATT

2-hr plasma isoniazid concentration, μg/mL

0.4 (0.2, 0.8)

0.5 (0.2, 0.8)

0.9

2.3 (1.2, 3.9)

1.7 (1.3, 2.8)

0.2

2-hr plasma rifampicin concentration, μg/mL

8.7 (5.4, 11.9)

9.7 (3.9, 11.6)

0.8

9.5 (5.3, 21.2)

11.3 (5.7, 15.2)

0.9

2-hr pyrazinamide concentration, μg/mL

40.4 (34.8, 46.9)

44.2 (38.4, 53.1)

0.7

39.8 (35.0, 44.7)

41.4 (34.4, 47.8)

0.8

2-hr ethambutol concentration, μg/mL

0.7 (0.4, 1.5)

0.6 (0.5, 0.9)

0.4

2.5 (1.7, 3.7)

3.2 (2.2, 4.8)

0.2

C _max isoniazid, μg/mL

3.4 (1.8, 5.0)

1.3 (0.7, 1.5)

0.05

3.2 (2.0, 4.7)

3.5 (1.8, 5.2)

0.6

C _max rifampicin, μg/mL

10.3 (6.8, 13.9)

11.5 (7.8, 14.3)

0.9

10.4 (7.7, 14.0)

12.8 (6.6, 15.3)

0.5

C _max pyrazinamide, μg/mL

50.1 (39.2, 67.5)

52.8 (43.5, 68.5)

0.8

46.7 (40.4, 52.6)

43.4 (38.4, 53.9)

0.5

C _max ethambutol, μg/mL

1.1 (0.7, 2.1)

1.2 (0.5, 1.9)

0.8

3.3 (2.3, 4.1)

3.7 (2.3, 4.9)

0.4

AUC _0–4 isoniazid, μg/mL*hr

1.3 (0.7, 2.4)

1.9 (1.5, 3.3)

0.2

7.9 (4.2, 13.2)

5.9 (4.5, 10.1)

0.3

AUC _0–4 rifampicin, μg/mL*hr

27.9 (19.1, 36.1)

30.2 (23.5, 34.1)

0.8

25.3 (16.6, 60.7)

30.6 (21.7, 44.1)

0.8

AUC _0–4 pyrazinamide, μg/mL*hr

159.9 (111.8, 207.0)

155.3 (125.3, 210.9)

0.9

137.8 (123.6, 158.3)

133.7 (121.4, 151.6)

0.5

AUC _0–4 ethambutol, μg/mL*hr

2.5 (1.5, 5.5)

2.1 (1.4, 3.7)

0.5

7.7 (4.9, 10.7)

10.0 (5.9, 10.9)

0.5

WAZ at baseline

−1.8 (−2.8, -1.1)

−1.9 (−3.2, -1.7)

0.3

−1.3(−1.9, -0.6)

−1.9 (−2.3, -1.8)

0.007

HAZ at baseline

−1.5 (−2.1, -0.2)

−1.2 (−1.9, -0.2)

0.8

−1.1 (−2.3, -0.2)

−1.5 (−1.9, -0.8)

0.5

Received BCG, n (%)

42 (76.4)

6 (66.7)

0.7

31 (70.4)

11 (64.7)

0.7

Mycobacterium confirmed, n (%)

9 (16.4)

5 (55.6)

0.01

8 (18.6)

4 (23.5)

0.7

Diagnosis, n (%)

0.9

0.5

Progressive pulmonary disease

30 (56.6)

5 (55.6)

17 (38.6)

10 (58.8)

Pleural effusion

7 (13.2)

1 (11.1)

1 (2.3)

1 (5.9)

Disseminated

16 (30.2)

3 (33.3)

2 (4.5)

1 (5.9)

Osteoarticular

0

0

9 (20.5)

2 (11.8)

Peripheral lymphadenopathy

0

0

15 (34.1)

3 (17.6)